Literature DB >> 19093702

Strategies to improve adherence and outcomes in patients with ulcerative colitis.

Sunanda V Kane1.   

Abstract

This review examines studies of patient adherence to 5-aminosalicylic acid therapy conducted outside the context of a controlled therapy trial, considers the reasons why patients do not adhere to their medication and its consequences, and interventions to improve adherence and disease outcomes. Non-adherence in the inflammatory bowel disease population tends to mirror other chronic illnesses, in the range of 40-60%. Factors that appear to affect adherence include younger age, single status, heavy pill burden, perception of lack of benefit and feeling uninformed about the effect of medication. Three important outcomes of non-adherence include increased risk for disease activity, increased healthcare costs and the possible increased risk of dysplasia/colorectal cancer. Strategies to improve adherence include patient education and 'health literacy', along with discussing patient misperceptions and fears on an individual basis, decreasing the daily regimen and switching to high-dose formulations, and incorporating patient self-management techniques into practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19093702     DOI: 10.2165/0003495-200868180-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  39 in total

1.  Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

Authors:  Stephen B Hanauer; William J Sandborn; Asher Kornbluth; Seymour Katz; Michael Safdi; Scott Woogen; Gino Regalli; Chyon Yeh; Nancy Smith-Hall; Funmilay Ajayi
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

2.  Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.

Authors:  David T Rubin; Andelka LoSavio; Nicole Yadron; Dezheng Huo; Stephen B Hanauer
Journal:  Clin Gastroenterol Hepatol       Date:  2006-10-23       Impact factor: 11.382

Review 3.  Compliance with treatment regimens in chronic asymptomatic diseases.

Authors:  N H Miller
Journal:  Am J Med       Date:  1997-02-17       Impact factor: 4.965

4.  Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.

Authors:  D Pinczowski; A Ekbom; J Baron; J Yuen; H O Adami
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

Review 5.  Mesalamine delivery systems: do they really make much difference?

Authors:  Altamash I Qureshi; Russell D Cohen
Journal:  Adv Drug Deliv Rev       Date:  2005-01-06       Impact factor: 15.470

6.  Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.

Authors:  A Robinson; D G Thompson; D Wilkin; C Roberts
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Is continuous sulfasalazine necessary in the management of patients with ulcerative colitis? Results of a preliminary study.

Authors:  R J Dickinson; A King; D G Wight; J O Hunter; G Neale
Journal:  Dis Colon Rectum       Date:  1985-12       Impact factor: 4.585

8.  Compliance to therapy in patients on a maintenance dose of sulfasalazine.

Authors:  P A van Hees; J H van Tongeren
Journal:  J Clin Gastroenterol       Date:  1982-08       Impact factor: 3.062

9.  What do patients want to know about their inflammatory bowel disease?

Authors:  A Martin; L Leone; I Castagliuolo; F Di Mario; R Naccarato
Journal:  Ital J Gastroenterol       Date:  1992 Nov-Dec

10.  Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease.

Authors:  Jau-Min Wong; Shu-Chen Wei
Journal:  J Formos Med Assoc       Date:  2003-09       Impact factor: 3.282

View more
  12 in total

1.  New keys to maintenance treatment in ulcerative colitis.

Authors:  Peter D R Higgins
Journal:  Dig Dis       Date:  2010-09-30       Impact factor: 2.404

2.  Satisfaction with patient-doctor relationships in inflammatory bowel diseases: examining patient-initiated change of specialist.

Authors:  Daniel R van Langenberg; Jane M Andrews
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

3.  Optimizing management of Crohn's disease within a project management framework: results of a pilot study.

Authors:  Laurie Keefer; Bethany Doerfler; Caroline Artz
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

4.  Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management.

Authors:  Anilga Tabibian; James H Tabibian; Linda J Beckman; Laura L Raffals; Konstantinos A Papadakis; Sunanda V Kane
Journal:  Dig Dis Sci       Date:  2015-01-06       Impact factor: 3.199

5.  Recent advances in the management of distal ulcerative colitis.

Authors:  Ioannis E Koutroubakis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-04-06

6.  Transition of Care in Inflammatory Bowel Disease.

Authors:  Bincy P Abraham; Stacy A Kahn
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

7.  Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.

Authors:  Sunanda V Kane; Michael Sumner; Dory Solomon; Matthew Jenkins
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

Review 8.  Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.

Authors:  Ashwin N Ananthakrishnan; Tamara Donaldson; Karen Lasch; Vijay Yajnik
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

Review 9.  Practical strategies for enhancing adherence to treatment regimen in inflammatory bowel disease.

Authors:  Rachel N Greenley; Jennifer H Kunz; Jennifer Walter; Kevin A Hommel
Journal:  Inflamm Bowel Dis       Date:  2013-06       Impact factor: 5.325

10.  Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.

Authors:  Axel Dignass; Robert Schnabel; Jacek Romatowski; Vladimir Pavlenko; Andrey Dorofeyev; Jelena Derova; Laimas Jonaitis; Karin Dilger; Tanju Nacak; Roland Greinwald
Journal:  United European Gastroenterol J       Date:  2017-03-30       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.